Eledon Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) on April 7, 2025, covering events occurring on April 1, 2025. The filing addresses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance regarding the audit firm.
Material Changes
- Dismissal of Auditor: The Audit Committee dismissed Crowe LLP as the independent registered public accounting firm effective April 1, 2025.
- Appointment of New Auditor: The Audit Committee appointed Deloitte & Touche LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2025, and related interim periods.
- Audit History: The reports issued by Crowe LLP for the fiscal years ended December 31, 2024, and December 31, 2023, were unqualified and did not contain adverse opinions, disclaimers, or modifications regarding uncertainty or scope.
- Disagreements: There were no disagreements with Crowe LLP on accounting principles, practices, or auditing procedures during the two most recent fiscal years or the interim period through April 1, 2025. No "reportable events" occurred.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on business outlook, or specific risk factors beyond the standard disclosure of the auditor change. The Company confirmed that no consultations were held with Deloitte regarding accounting principles or reportable events prior to their appointment.
Investor Verification Checklist
- Verify the transition timeline and responsibilities between Crowe LLP and Deloitte & Touche LLP.
- Review the letter from Crowe LLP (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the dismissal.
- Monitor future filings for the first audit report issued by Deloitte & Touche LLP.
- Confirm that no undisclosed disagreements or reportable events exist that may impact the integrity of prior financial statements.